NVNO,enVVeno Medical Corporation | Healthcare

Healthcare

NVNO

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

enVVeno Medical CorporationNVNO

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.

The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease.

Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg.

The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.

enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Latest News >

Lufax Holding Swings to Q2 Loss

Aug 22, 2024

03:43 AM EDT, 08/22/2024 (MT Newswires) -- Lufax Holding ( LU ) reported a Q2 loss late Wednesday of 0.69 Chinese renminbi ($0.09) per diluted share, swinging from earnings of 0.84 renminbi a year earlier. Total income for the quarter ended June 30 was 5.98 billion renminbi, down from 9.27 billion renminbi a year earlier. Analyst estimates were not available...

Halozyme Therapeutics Insider Sold Shares Worth $1,228,020, According to a Recent SEC Filing

Aug 22, 2024

03:32 AM EDT, 08/22/2024 (MT Newswires) -- Michael J. LaBarre, Chief Technical Officer, Senior Vice President, on August 20, 2024, sold 20,000 shares in Halozyme Therapeutics ( HALO ) for $1,228,020. Following the Form 4 filing with the SEC, LaBarre has control over a total of 168,176 shares of the company, with 168,176 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/xslF345X05/form4-08212024_100827.xml Price:...

Ross Stores Fiscal Q2 Earnings, Sales Rise

Aug 22, 2024

04:46 PM EDT, 08/22/2024 (MT Newswires) -- Ross Stores ( ROST ) reported fiscal Q2 earnings late Thursday of $1.59 per diluted share, up from $1.32 a year earlier. Analysts polled by Capital IQ expected $1.49. Sales for the quarter ended Aug. 3 rose to $5.29 billion from $4.93 billion a year earlier. Analysts surveyed by Capital IQ expected $5.25...

Procter & Gamble Insider Sold Shares Worth $1,611,303, According to a Recent SEC Filing

Aug 22, 2024

05:07 PM EDT, 08/22/2024 (MT Newswires) -- Marc S. Pritchard, Chief Brand Officer, on August 20, 2024, sold 9,522 shares in Procter & Gamble ( PG ) for $1,611,303. Following the Form 4 filing with the SEC, Pritchard has control over a total of 219,156 shares of the company, with 172,665 shares held directly and 46,490 controlled indirectly. SEC Filing:...